Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcoma
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljae386 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Louise van der Weyden und 23 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK. Hauptthemen laut MEDLINE: Leiomyosarcoma, Skin Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Medical Research Council.
Abstract (Originalsprache)
Background
Cutaneous leiomyosarcoma (cLMS) is a rare soft-tissue neoplasm, showing smooth muscle differentiation, that arises from the mesenchymal cells of the dermis. To date, genetic investigation of these tumours has involved studies with small sample sizes and limited analyses that identified recurrent somatic mutations in RB1 and TP53, copy number gain of MYOCD and IGF1R, and copy number loss of PTEN.
Objectives
To better understand the molecular pathogenesis of cLMS, we comprehensively explored the mutational landscape of these rare tumours to identify candidate driver events.
Methods
In this retrospective, multi-institutional study, we performed whole-exome sequencing and RNA sequencing in 38 cases of cLMS.
Results
TP53 and RB1 were identified as significantly mutated and thus represent validated driver genes of cLMS. COSMIC mutational signatures SBS7a/b and DBS1 were recurrent; thus, ultraviolet light exposure may be an aetiological factor driving cLMS. Analysis of significantly recurrent somatic copy number alterations, which represent candidate driver events, found focal (< 10 Mb) deletions encompassing TP53 and KDM6B, and amplifications encompassing ZMYM2, MYOCD, MAP2K4 and NCOR1. A larger (24 Mb) recurrent deletion encompassing CYLD was also identified as significant. Significantly recurrent broad copy number alterations, involving at least half of a chromosome arm, included deletions of 6p/q, 10p/q, 11q, 12q, 13q and 16p/q, and amplification of 15q. Notably PTEN is located on 10q, RB1 on 13q and IGFR1 on 15q. Fusion gene analysis identified recurrent CRTC1/CRTC3::MAML2 fusions, as well as many novel fusions in individual samples.
Conclusions
Our analysis of the largest number of cases of cLMS to date highlights the importance of large cohort sizes and exploration beyond small targeted gene panels when performing molecular analyses, as it allowed a comprehensive exploration of the mutational landscape of these tumours and identification of novel candidate driver events. It also uniquely afforded the opportunity to compare the molecular phenotype of cLMS with LMS of other tissue types, such as uterine and soft-tissue LMS. Given that molecular profiling has resulted in the development of novel targeted treatment approaches for uterine and soft-tissue LMS, our study now allows the same opportunities to become available for patients with cLMS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
- Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
- Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
ORCID-Profile: Louise van der Weyden, Martin Del Castillo Velasco-Herrera, Saamin Cheema, Alastair Droop, Ingrid Ferreira, David J Adams
Förderung
- Wellcome Trust
- Medical Research Council
Zitieren
APA
van der Weyden, L., Del Castillo Velasco-Herrera, M., Cheema, S., Wong, K., Boccacino, J. M., Offord, V., Droop, A., Jones, D. R. A., Vermes, I., Anderson, E., Hardy, C., de Saint Aubain, N., Ferguson, P. M., Clarke, E. L., Merchant, W., Mogler, C., Frew, D., Harms, P. W., Monteagudo, C., …, & Adams, D. J. (2025). Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcoma. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae386
Vancouver
van der Weyden L, Del Castillo Velasco-Herrera M, Cheema S, Wong K, Boccacino JM, Offord V, et al. Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcoma. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljae386
BibTeX
@article{vanderWeyden2025,
author = {van der Weyden, Louise and Del Castillo Velasco-Herrera, Martin and Cheema, Saamin and Wong, Kim and Boccacino, Jacqueline M and Offord, Victoria and Droop, Alastair and Jones, David R A and Vermes, Ian and Anderson, Elizabeth and Hardy, Claire and de Saint Aubain, Nicolas and Ferguson, Peter M and Clarke, Emily L and Merchant, William and Mogler, Carolin and Frew, Derek and Harms, Paul W and Monteagudo, Carlos and Billings, Steven D and Arends, Mark J and Ferreira, Ingrid and Brenn, Thomas and Adams, David J},
title = {Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcoma},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljae386}
}
EUVIMED